Effectiveness and Safety of Drug-Eluting Stents in Ontario
The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The placement of drug-eluting stents decreases the frequency of repeat revascularization procedures in patients undergoing percutaneous coronary intervention (PCI) in randomized clinical trials. However, there is uncertainty about the effectiveness of drug-eluting stents, and increasing concern about their safety, in routine clinical practice. METHODS: From the Cardiac Care Network of Ontario's population-based clinical registry of all patients undergoing PCI in Ontario, Canada, we identified a well-balanced cohort of 3751 pairs of patients, matched on the basis of propensity score, who received either bare-metal stents alone or drug-eluting stents alone during an index PCI procedure between December 1, 2003, and March 31, 2005. The primary outcomes of the study were the rates of target-vessel revascularization, myocardial infarction, and death. RESULTS: The 2-year rate of target-vessel revascularization was significantly lower among patients who received drug-eluting stents than among those who received bare-metal stents (7.4% vs. 10.7%, P<0.001). Drug-eluting stents were associated with significant reductions in the rate of target-vessel revascularization among patients with two or three risk factors for restenosis (i.e., presence of diabetes, small vessels [<3 mm in diameter], and long lesions [> or =20 mm]) but not among lower-risk patients. The 3-year mortality rate was significantly higher in the bare-metal-stent group than in the drug-eluting-stent group (7.8% vs. 5.5%, P<0.001), whereas the 2-year rate of myocardial infarction was similar in the two groups (5.2% and 5.7%, respectively; P=0.95). CONCLUSIONS: Drug-eluting stents are effective in reducing the need for target-vessel revascularization in patients at highest risk for restenosis, without a significantly increased rate of death or myocardial infarction.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Approximately 15% of patients with T2DM will require target vessel revascularization within 2 years after bare metal stenting,290”
From Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association (2020) · cites this paper as [290]
Citations
Cites
Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data
Quan, H., Sundararajan, V., Halfon, P., Fong, A., Burnand, B., Luthi, J.-C., Saunders, L. D., Beck, C. A., Feasby, T. E., & Ghali, W. A. (2005) · Medical Care · doi:10.1097/01.mlr.0000182534.19832.83 · Cited by 10,669
Survival Analysis, Techniques for Censored and Truncated Data
Rao, M. B. (1998) · Technometrics · doi:10.1080/00401706.1998.10485206 · Cited by 3,617
Iakovou, I. (2005) · JAMA · doi:10.1001/jama.293.17.2126 · Cited by 3,132
WRITING COMMITTEE MEMBERS, Smith, S. C., Feldman, T. E., Hirshfeld, J. W., Jacobs, A. K., Kern, M. J., King, S. B., Morrison, D. A., O’Neill, W. W., Schaff, H. V., et al. (2006) · Circulation · doi:10.1161/circulationaha.105.170815 · Cited by 2,218
An Assessment of Clinically Useful Measures of the Consequences of Treatment
Laupacis, A., Sackett, D. L., & Roberts, R. S. (1988) · New England Journal of Medicine · doi:10.1056/nejm198806303182605 · Cited by 1,681
Safety and Efficacy of Sirolimus- and Paclitaxel-Eluting Coronary Stents
Stone, G. W., Moses, J. W., Ellis, S. G., Schofer, J., Dawkins, K. D., Morice, M.-C., Colombo, A., Schampaert, E., Grube, E., Kirtane, A. J., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067193 · Cited by 1,631
Late Clinical Events After Clopidogrel Discontinuation May Limit the Benefit of Drug-Eluting Stents
Pfisterer, M., Brunner-La Rocca, H. P., Buser, P. T., Rickenbacher, P., Hunziker, P., Mueller, C., Jeger, R., Bader, F., Osswald, S., & Kaiser, C. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.10.026 · Cited by 1,303
Long-Term Outcomes with Drug-Eluting Stents versus Bare-Metal Stents in Sweden
Lagerqvist, B., James, S. K., Stenestrand, U., Lindbäck, J., Nilsson, T., & Wallentin, L. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067722 · Cited by 1,197
Grines, C. L., Bonow, R. O., Casey, D. E., Gardner, T. J., Lockhart, P. B., Moliterno, D. J., O’Gara, P., & Whitlow, P. (2007) · Circulation · doi:10.1161/circulationaha.106.180944 · Cited by 1,140
Austin, P. C., Grootendorst, P., & Anderson, G. M. (2007) · Statistics in Medicine · doi:10.1002/sim.2580 · Cited by 1,137
Self-citationAnalysis of 14 Trials Comparing Sirolimus-Eluting Stents with Bare-Metal Stents
Kastrati, A., Mehilli, J., Pache, J., Kaiser, C., Valgimigli, M., Kelbæk, H., Menichelli, M., Sabaté, M., Suttorp, M. J., Baumgart, D., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067484 · Cited by 1,006
Clopidogrel Use and Long-term Clinical Outcomes After Drug-Eluting Stent Implantation
Eisenstein, E. L., Anstrom, K. J., Kong, D. F., Shaw, L. K., Tuttle, R. H., Mark, D. B., Kramer, J. M., Harrington, R. A., Matchar, D. B., Kandzari, D. E., et al. (2007) · JAMA · doi:10.1001/jama.297.2.joc60179 · Cited by 870
Spertus, J. A., Kettelkamp, R., Vance, C., Decker, C., Jones, P. G., Rumsfeld, J. S., Messenger, J. C., Khanal, S., Peterson, E. D., Bach, R. G., et al. (2006) · Circulation · doi:10.1161/circulationaha.106.618066 · Cited by 854
Camenzind, E., Steg, P. G., & Wijns, W. (2007) · Circulation · doi:10.1161/circulationaha.106.666800 · Cited by 818
A Pooled Analysis of Data Comparing Sirolimus-Eluting Stents with Bare-Metal Stents
Spaulding, C., Daemen, J., Boersma, E., Cutlip, D. E., & Serruys, P. W. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066633 · Cited by 704
A hierarchical Bayesian meta-analysis of randomised clinical trials of drug-eluting stents
Babapulle, M. N., Joseph, L., Bélisle, P., Brophy, J. M., & Eisenberg, M. J. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16850-5 · Cited by 645
Sirolimus-Eluting versus Uncoated Stents in Acute Myocardial Infarction
Spaulding, C., Henry, P., Teiger, E., Beatt, K., Bramucci, E., Carrié, D., Slama, M. S., Merkely, B., Erglis, A., Margheri, M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062006 · Cited by 564
Austin, P. C., & Mamdani, M. M. (2006) · Statistics in Medicine · doi:10.1002/sim.2328 · Cited by 560
Self-citationAustin, P. C., Daly, P. A., & Tu, J. V. (2002) · American Heart Journal · doi:10.1067/mhj.2002.123839 · Cited by 525
Self-citationLate Thrombosis of Drug-Eluting Stents: A Meta-Analysis of Randomized Clinical Trials
Bavry, A. A., Kumbhani, D. J., Helton, T. J., Borek, P. P., Mood, G. R., & Bhatt, D. L. (2006) · The American Journal of Medicine · doi:10.1016/j.amjmed.2006.01.023 · Cited by 490 · cited 1×
“Address reprint requests to Dr. Tu at the Institute for Clinical Evaluative Sciences, G106-2075 Bayview Ave., Toronto, ON M4N 3M5, Canada, or at tu@ices.on.ca. N Engl J Med 2007; 357:1393-402.”
BackgroundPaclitaxel-Eluting versus Uncoated Stents in Primary Percutaneous Coronary Intervention
Laarman, G. J., Suttorp, M. J., Dirksen, M. T., van Heerebeek, L., Kiemeneij, F., Slagboom, T., van der Wieken, L. R., Tijssen, J. G. P., Rensing, B. J., & Patterson, M. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062598 · Cited by 437
Clinical restenosis after coronary stenting: perspectives from multicenter clinical trials
Cutlip, D. E., Chauhan, M. S., Baim, D. S., Ho, K. K. L., Popma, J. J., Carrozza, J. P., Cohen, D. J., & Kuntz, R. E. (2002) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(02)02597-4 · Cited by 423
ACC/AHA/SCAI Practice Guidelines, February 21, 2006
(2006) · Circulation · doi:10.1161/circulationaha.106.173220 · Cited by 422
Bare metal stent restenosis is not a benign clinical entity
Chen, M. S., John, J. M., Chew, D. P., Lee, D. S., Ellis, S. G., & Bhatt, D. L. (2006) · American Heart Journal · doi:10.1016/j.ahj.2005.08.011 · Cited by 413
Survival Analysis Techniques for Censored and Truncated Data
Klein, J. P., & Moeschberger, M. L. (2003) · Thammasat University Digital Collections · Cited by 360
Stent Thrombosis Redux — The FDA Perspective
Farb, A., & Boam, A. B. (2007) · New England Journal of Medicine · doi:10.1056/nejmp068304 · Cited by 284
Unanswered Questions — Drug-Eluting Stents and the Risk of Late Thrombosis
Maisel, W. H. (2007) · New England Journal of Medicine · doi:10.1056/nejmp068305 · Cited by 268
ESC guidelines for percutaneous coronary interventions: reply
Silber, S. (2005) · European Heart Journal · doi:10.1093/eurheartj/ehi564 · Cited by 213
[Guidelines for percutaneous coronary interventions].
Silber, S., Albertsson, P., Fernández‐Avilés, F., Camici, P. G., Colombo, A., Hamm, C. W., Jørgensen, E. O., Marco, J., Nordrehaug, J.-E., Rużyłło, W., et al. (2005) · PubMed · Cited by 201
Camenzind, E., Steg, P. G., & Wijns, W. (2007) · Circulation · doi:10.1161/circulationaha.107.716019 · Cited by 162
Williams, D. O., Abbott, J. D., & Kip, K. E. (2006) · Circulation · doi:10.1161/circulationaha.106.667915 · Cited by 150
(1993) · PubMed · Cited by 147
Trading Restenosis for Thrombosis? New Questions about Drug-Eluting Stents
Shuchman, M. (2006) · New England Journal of Medicine · doi:10.1056/nejmp068234 · Cited by 134
Can we afford to eliminate restenosis?
Greenberg, D., Bakhai, A., & Cohen, D. J. (2004) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2003.11.020 · Cited by 105
Debating the Risks of Drug-Eluting Stents
Shuchman, M. (2007) · New England Journal of Medicine · doi:10.1056/nejmp068300 · Cited by 80
Research works printed but not linked: 1
- Wilkins R, 1993, Health Rep, 5, 157
Cited by
Palmerini, T., Biondi-Zoccai, G., Riva, D. D., Stettler, C., Sangiorgi, D., D'Ascenzo, F., Kimura, T., Briguori, C., Sabatè, M., Kim, H.-S., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60324-9 · Cited by 959
Drug-Eluting Coronary-Artery Stents
Stefanini, G. G., & Holmes, D. R. (2013) · New England Journal of Medicine · doi:10.1056/nejmra1210816 · Cited by 728
Kirtane, A. J., Gupta, A., Iyengar, S., Moses, J. W., Leon, M. B., Applegate, R., Brodie, B., Hannan, E., Harjai, K., Jensen, L. O., et al. (2009) · Circulation · doi:10.1161/circulationaha.108.826479 · Cited by 577
Self-citationGarg, S., & Serruys, P. W. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.06.007 · Cited by 501
Berger, M. L., Mamdani, M., Atkins, D., & Johnson, M. L. (2009) · Value in Health · doi:10.1111/j.1524-4733.2009.00600.x · Cited by 409
“For example, rich clinical information for defined sets of patients can be merged into administrative data to limit the need for prospective follow-up of outcomes that are routinely collected in administrative datasets [ 30 ].”
Background
Metadata
- Authors
- Tu, J. V., Bowen, J., Chiu, M., Ko, D. T., Austin, P. C., He, Y., Hopkins, R., Tarride, J.-E., Blackhouse, G., Lazzam, C., Cohen, E. A., & Goeree, R.
- Affiliations
- Sunnybrook Health Science Centre (CA)
- St. Joseph’s Healthcare Hamilton (CA)
- Institute for Clinical Evaluative Sciences (CA)
- Trillium Health Centre (CA)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-10-04
- Volume
- 357
- Issue
- 14
- Pages
- 1393-1402
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2082511254
- Cited by
- 383
- References
- 35
- Citations by year
- 2024: 1 · 2023: 1 · 2022: 2 · 2021: 5 · 2020: 11 · 2019: 7 · 2018: 5 · 2017: 13 · 2016: 15 · 2015: 28 · 2014: 15 · 2013: 15 · 2012: 34
- FWCI
- 67.09
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Coronary Interventions and Diagnostics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Keywords
- drug-eluting stents, bare-metal stents, percutaneous coronary intervention, target vessel revascularization, restenosis, myocardial infarction, mortality, diabetes mellitus, long coronary lesions, propensity score matching, clinical registries, Ontario
- MeSH terms
- Female, Follow-Up Studies, Humans, Male, Middle Aged, Myocardial Infarction, Ontario, Prosthesis Design, Registries, Risk Factors, Stents, Angioplasty, Balloon, Coronary, Drug Delivery Systems, Myocardial Ischemia, Disease-Free Survival, Coronary Restenosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.